BMS-201620: A selective beta 3 agonist

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 13, 2004, Pages 3525-3529

  Washburn, W N ^a   Sun, C Q ^a   Bisacchi, G ^a   Wu, G ^a   Cheng, P T ^a   Sher, P M ^a   Ryono, D ^a   Gavai, A V ^a   Poss, K ^a   Girotra, R N ^a   McCann, P J ^a   Mikkilineni, A B ^a   Dejneka, T C ^a   Wang, T C ^a   Merchant, Z ^a   Morella, M ^a   Arbeeny, C M ^a   Harper, T W ^a   Slusarchyk, D A ^a   Skwish, S ^a   Russell, A D ^a   Allen, G T ^a   Tesfamariam, B ^a   Frohlich, B H ^a   Abboa Offei, B E ^a   Cap, M ^a   Waldron, T L ^a   George, R J ^a   Young, D ^a   Dickinson, K E ^a   Seymour, A A ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BMS 201620; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SAFETY; EVALUATION; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-AGONISTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GLYCINE; HAPLORHINI; HUMANS; METHYLATION; RECEPTORS, ADRENERGIC, BETA-3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942559065     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.074     Document Type: Article

References (21)

1. Yanovski S.Z., Yanoski J.A. N. Engl. J. Med. 346:2002;591
2. Friedman J.M. Nature. 404:2000;632
3. Amos A.F., McCarty D.J., Zimmet P. Diabet. Med. 14:1997;S7
4. For recent reviews, see: Lowell B.B., Bachman E.S. J. Biol. Chem. 278:2003;29385
5. de Souza C.J., Burkey B.F. Curr. Pharm. Des. 7:2001;1433
6. Weyer C., de Souza C.J. Drug Dev. Res. 51:2000;80
7. Bray G.A., Tartaglia L.A. Nature. 404:2000;672
8. Weyer C., Gautier J.F., Danforth E. Jr. Diabet. Metab. 25:1999;11
9. Kordik C.P., Reitz A.B. J. Med. Chem. 42:1999;181
10. Weber A.E. Annu. Rep. Med. Chem. 33:1998;193
11. Washburn W.N., Sher P.M., Poss K., Girotra R.N., McCann P.J., Gavai A.V., Mikkilineni A.B., Mathur A., Cheng P., Dejneka T.C., Sun C.Q., Wang T.C., Harper T.W., Russell A.D., Slusarchyk D.A., Skwish S., Allen G.T., Hillyer D.E., Frohlich B.H., Abboa-Offei B.E., Cap M., Waldron T.L., George R.J., Tesfamariam B., Ciosek C.P., Young D.A., Dickinson K.E., Seymour A.A., Arbeeny C.M., Gregg R.E. Bioorg. Med. Chem. Lett. 11:2001;3035
12. Gavai A.V., Sher P.M., Mikkilineni A.B., Poss K.M., McCann P.J., Girotra R.N., Fisher L.G., Wu G., Bednarz M.S., Mathur A., Wang T.C., Sun C.Q., Slusarchyk D.A., Young D.A., Dickinson K.E., Seymour A.A., Arbeeny C.M., Washburn W.N. Bioorg. Med. Chem. Lett. 11:2001;3041
13. 7 IA is the percent of the maximal stimulation achieved with isoproterenol
14. 3 adrenergic receptor reported by Emorine L.T., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A.D. Science. 245:1989;1118
15. Sher P.M., Fisher L.G., Skwish S., Michel I.M., Seiler S.M., Washburn W.N., Dickinson K.E. J. Med. Chem. Res. 7:1997;109
16. For the synthesis of the enantiomers of i, see Crast L. B. U.S. Patent 3, 517, 023, 1970; Chem. Abstr. 1970, 466567.
17. Preparation of 13 analogous to 25 of Ref. 3
18. Spectral data were fully consistent with structures
19. Tesfamariam B., Allen G.T. Br. J. Pharmacol. 112:1994;55
20. Lipworth B.J., McFarlane L.C., Coutie W.J., McDevitt D. Eur. J. Clin. Pharmacol. 37:1989;297
21. Unpublished work communicated by Dr. Peter Slugg